SUPERSEDED - Reference segmentations of white matter hyperintensities from a subset of 20 subjects scanned three consecutive years

Abstract

SUPERSEDED - THIS ITEM HAS BEEN REPLACED BY http://datashare.is.ed.ac.uk/handle/10283/2214. This dataset contains structural magnetic resonance imaging (MRI)-derived data from 20 participants enrolled in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) project. These data are likelihood maps of cerebrospinal fluid, grey matter and normal-appearing white matter, and binary masks of white matter hyperintensities (WMH), all obtained from MRI acquired at three consecutive study visits spaced 12 months apart.

## Acknowledgements ## Investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in the analysis or processing which produced the derived data presented here. A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf .

Data collection and sharing for ADNI was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.